Atopic Dermatitis

The AJMC® Atopic Dermatitis compendium is a comprehensive resource for clinical news and expert insights for the chronic skin condition that typically develops in early childhood.

Latest News

Pediatric atopic dermatitis | Image Credit: Maggie L. Shaw/sora.chatgpt.com
Pediatric Atopic Dermatitis Linked to Allergy Development

June 13th 2025

Outcomes were evaluated among children born between April 1980 and June 2019 by using data from 12 observational birth cohorts from the Environmental Influences on Child Health Outcomes Children’s Respiratory and Environmental Workgroup.

Atopic Dermatitis Image Credit: wladimir1804-stock.adobe.com
Oral Ivarmacitinib Shows Promise in Atopic Dermatitis

June 6th 2025

Through data from genome-wide association studies, the researchers identified several single nucleotide polymorphisms contributing to the causal relationship between insomnia and atopic dermatitis. | Image credit: amenic181 - stock.adobe.com
Study Explores Link Between Insomnia, Atopic Dermatitis

May 31st 2025

The apparent divergence between subjective and objective measures of atopic dermatitis severity underscores the need for more precise assessment methods, the authors explained. | Image credit: Evgeniya Primavera - stock.adobe.com
AI Model Can Help Classify Atopic Dermatitis Lesion Severity

May 29th 2025

Adolescent patients were more likely to be most bothered by feelings of anxiety or atopic dermatitis affecting their daily activities. | Image Credit: InfiniteStudio - stock.adobe.com
Patient-Reported Experiences Show Psychological Impact of Atopic Dermatitis on Adolescents

May 22nd 2025

Topical Therapies for the Treatment of Atopic Dermatitis: Balancing Safety, Efficacy, and Access

Develop a deeper understanding of the atopic dermatitis (AD) patient journey, explore topical therapies and treatment sequencing advancements, and gain insight regarding the payer’s perspective on AD therapies.

Atopic Dermatitis Payer Perspectives

More News

cream.
April 25th 2022

Improved Severity of Atopic Dermatitis Achieved With Adjuvant Dupilumab, Tacrolimus

Matthew Gavidia
More patients with atopic dermatitis achieved mild disease severity by 1 month of treatment with adjuvant dupilumab and tacrolimus vs dupilumab alone.
Elaine Siegfried, MD.
April 20th 2022

Dr Elaine Siegfried on Considerations for Systemic Therapy Use in Pediatric Atopic Dermatitis

Matthew Gavidia
Elaine Siegfried, MD, professor of pediatrics and dermatology, Saint Louis University Health Sciences Center, discusses several pediatric patient populations with atopic dermatitis who are candidates for the use of systemic therapies.
Physician examining skin of patient.
April 18th 2022

Investigating Lifestyle Behaviors Associated With Moderate to Severe Atopic Dermatitis

Matthew Gavidia
Several modifiable lifestyle factors were associated with moderate to severe atopic dermatitis in a patient cohort from the Netherlands, including smoking, alcohol consumption, and stress.
Elaine Siegfried, MD.
April 14th 2022

Dr Elaine Siegfried Overviews Pathology, Targeted Therapy in Atopic Dermatitis

Matthew Gavidia
Elaine Siegfried, MD, professor of pediatrics and dermatology, Saint Louis University Health Sciences Center, explains current knowledge on the pathology of atopic dermatitis and use of targeted biologic therapies.
Doctor talking to a patient
April 11th 2022

Dupilumab Creates Rapid, Sustained Responses in Asthma, CRSwNP, and AD

Laura Joszt, MA
Across 3 disease states, dupilumab has been shown to create rapid, clinically meaningful responses that were sustained, which could improve adherence and the patient-provider relationship.
Robert Sidbury, MD, MPH.
April 8th 2022

Dr Robert Sidbury Discusses Impact of New AAD Guidelines on Atopic Dermatitis Treatment

Matthew Gavidia
Robert Sidbury, MD, MPH, Chief, Division of Dermatology, Seattle Children's Hospital, discussed how new guidelines issued by the American Academy of Dermatology (AAD) regarding comorbidity risk in patients with atopic dermatitis will influence the condition's treatment.
woman scratching arm
April 5th 2022

Baricitinib Linked With Improved Skin Pain Severity, Positive QOL in Atopic Dermatitis

Matthew Gavidia
Patients with atopic dermatitis who achieved rapid changes in skin pain severity with the Janus kinase inhibitor baricitinib were associated with clinically significant improvement in Dermatology Life Quality Index scores.
Child cutouts.
April 2nd 2022

Severity of Pediatric Atopic Dermatitis Underestimated by Physicians

Matthew Gavidia
Only half of pediatric patients with atopic dermatitis who fit the criteria of having severe disease were identified as such by managing physicians.
Black patient and doctor.
March 31st 2022

Ruxolitinib Cream Improves AD Across Body Regions, Shows Efficacy, Safety in Black Patients

Matthew Gavidia
Findings of 2 abstracts presented at the 2022 American Academy of Dermatology (AAD) Annual Meeting showed that ruxolitinib cream (​​Opzelura) demonstrated significant improvement vs vehicle in patients with atopic dermatitis of Black race and across anatomic regions.
Robert Sidbury, MD, MPH, Chief, Division of Dermatology, Seattle Children's Hospital.
March 25th 2022

Dr Robert Sidbury Discusses Payer Considerations for Dermatologists Managing Patients With Atopic Dermatitis

Matthew Gavidia
Robert Sidbury, MD, MPH, chief, Division of Dermatology, Seattle Children's Hospital, spoke on considerations for dermatologists in seeking payer coverage of novel, expensive therapies for atopic dermatitis.
Houses and apartments.
March 23rd 2022

House Dust Mite Sublingual Immunotherapy Shows Promise in Atopic Dermatitis

Matthew Gavidia
Sublingual immunotherapy with Dermatophagoides pteronyssinus extract was associated with significant improvements in disease severity among patients with atopic dermatitis sensitized to the house dust mite.
Robert Sidbury, MD, MPH.
March 17th 2022

Dr Robert Sidbury Addresses Quality-of-Life Burden in Atopic Dermatitis

Matthew Gavidia
Along with common symptoms of itch and pain, patients with atopic dermatitis experience significant work productivity and attention issues that affect overall quality of life, said Robert Sidbury, MD, MPH, chief, Division of Dermatology, Seattle Children's Hospital.
Person clenching hand.
March 15th 2022

Upadacitinib Shows Sustained Efficacy, Safety in Moderate to Severe Atopic Dermatitis

Matthew Gavidia
Longer-term findings of the Measure Up 1 and 2 studies showed the JAK inhibitor upadacitinib to be safe and effective after 52 weeks in the treatment of adults and adolescents with moderate to severe atopic dermatitis.
Robert Sidbury, MD, MPH.
March 13th 2022

Dr Robert Sidbury on Psychosocial, Behavioral Issues Linked With Atopic Dermatitis

Matthew Gavidia
Robert Sidbury, MD, MPH, chief, Division of Dermatology, Seattle Children's Hospital, discussed the psychosocial and behavioral issues faced by patients with atopic dermatitis, particularly those with severe disease.
Study Examines Dupilumab's Effect on EoE When Given for AD, Other Conditions
March 11th 2022

Study Examines Dupilumab's Effect on EoE When Given for AD, Other Conditions

Allison Inserro
Administering dupilumab for other atopic conditions, including atopic dermatitis (AD) and asthma, in patients who also have eosinophilic esophagitis (EoE), resulted in improved EoE symptoms.
Person with itchy skin.
March 9th 2022

Skin Barrier Function in Moderate to Severe AD Significantly Improved With Dupilumab

Matthew Gavidia
Dupilumab was shown to significantly improve factors of skin barrier function, including transepidermal water loss, lipid composition, and filaggrin, among patients with moderate to severe atopic dermatitis.
Nurse and patient.
March 4th 2022

Multidisciplinary Approach Identifies Allergic, Immunology Burden in Severe AD

Matthew Gavidia
Patients with severe atopic dermatitis showed significant associations with concomitant contact dermatitis and immune dysfunction after undergoing a multidisciplinary evaluation between allergy, immunology, and dermatology specialists.
Child.
March 1st 2022

Significant Disease Burden Found in Children With Moderate to Severe AD

Matthew Gavidia
Uncontrolled disease burden was a major unmet need among children with moderate to severe atopic dermatitis (AD) who were unresponsive to topical therapies.
Depression.
February 25th 2022

Worse Health-Related QOL, Mental Health in Patients With AD During the Pandemic

Matthew Gavidia
Polish patients with atopic dermatitis reported lower overall health and impaired quality of life related to mental health in the first year of the COVID-19 pandemic.
Robert Sidbury, MD, MPH.
February 24th 2022

Dr Robert Sidbury Discusses Utilization, Efficacy of Biologics for Atopic Dermatitis

Matthew Gavidia
Robert Sidbury, MD, MPH, chief, Division of Dermatology, Seattle Children's Hospital, speaks on the efficacy of biologics in the treatment of atopic dermatitis and other recently approved therapeutics.
Robert Sidbury, MD, MPH.
February 18th 2022

Dr Robert Sidbury on Risk Factors, Diagnosis of Atopic Dermatitis

Matthew Gavidia
Robert Sidbury, MD, MPH, chief of the Division of Dermatology at Seattle Children's Hospital, discusses risk factors involved in the pathogenesis of atopic dermatitis and several diagnostic methods.
Rural land.
February 17th 2022

Jobs in Forestry, Agriculture Linked With Increased AD Risk in Workers' Children

Matthew Gavidia
Japanese children of parents whose family business was primarily industry, including agriculture, forestry, and fisheries, had a greater risk of atopic dermatitis (AD) development.
Child.
February 12th 2022

AD Severity Linked With Sleep, Attention Issues in Young Children

Matthew Gavidia
Children with moderate to severe atopic dermatitis were found to be more likely to report suboptimal sleep and attention regulation outcomes.
Robert Sidbury, MD, MPH.
February 11th 2022

Dr Robert Sidbury Explains Pathophysiology, Comorbidity Risk of Atopic Dermatitis

Matthew Gavidia
Robert Sidbury, MD, MPH, chief, Division of Dermatology, Seattle Children's Hospital, speaks on the inflammatory mechanisms of atopic dermatitis and risk of comorbidities in affected patients.
FDA
February 3rd 2022

FDA Approves Abrocitinib for Adults With Moderate to Severe Atopic Dermatitis

Matthew Gavidia
The JAK1 inhibitor abrocitinib (Cibinqo) was recently approved by the FDA for the treatment of adults with refractory, moderate to severe atopic dermatitis.
Stethoscope.
January 31st 2022

Social Determinants May Influence Health Care Utilization, Symptom Burden in Patients With Asthma and Eczema

Matthew Gavidia
Minority patients and those with low income were more likely than White and high-income counterparts to report adverse outcomes in the management of asthma and eczema.
Flare.
January 29th 2022

Understanding, Managing Flares in Atopic Dermatitis

Matthew Gavidia
Researchers review current knowledge on the management of flares in atopic dermatitis, including treatment and unmet needs.
Health cross symbol.
January 27th 2022

Dupilumab Significantly Reduces Hospitalization Rates in Patients With Atopic Dermatitis

Matthew Gavidia
Patients with atopic dermatitis (AD) treated with dupilumab showed reduced hospitalization rates and shorter duration of AD-related hospitalizations vs those treated with control therapies.
Health care cost.
January 21st 2022

Substantial Cost Burden, Health Care Utilization Found in Patients With Severe Atopic Dermatitis

Matthew Gavidia
Patients with atopic dermatitis were associated with significant economic burden primarily driven by outpatient visits and pharmacy use, which increased with disease severity.
Physician, parent, and sick child.
January 19th 2022

Early-Life Infection Linked With Atopic Dermatitis Development in Infants, Children

Matthew Gavidia
Incidence of infectious diseases, skin infections, and systemic antibiotic exposure were all associated with the development of atopic dermatitis among infants and young children.
<12345678>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo